167 related articles for article (PubMed ID: 33898306)
1. Lung Adenocarcinoma Patient Harboring
Zhao L; Wang Z; Du H; Chen S; Wang P
Front Oncol; 2021; 11():605853. PubMed ID: 33898306
[TBL] [Abstract][Full Text] [Related]
2. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.
Gallant JN; Sheehan JH; Shaver TM; Bailey M; Lipson D; Chandramohan R; Red Brewer M; York SJ; Kris MG; Pietenpol JA; Ladanyi M; Miller VA; Ali SM; Meiler J; Lovly CM
Cancer Discov; 2015 Nov; 5(11):1155-63. PubMed ID: 26286086
[TBL] [Abstract][Full Text] [Related]
3. A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an
Chen D; Li XL; Wu B; Zheng XB; Wang WX; Chen HF; Dong YY; Xu CW; Fang MY
Front Oncol; 2020; 10():867. PubMed ID: 32656077
[No Abstract] [Full Text] [Related]
4. The landscape of kinase domain duplication in Chinese lung cancer patients.
Wu D; Xie Y; Jin C; Qiu J; Hou T; Du H; Chen S; Xiang J; Shi X; Liu J
Ann Transl Med; 2020 Dec; 8(24):1642. PubMed ID: 33490154
[TBL] [Abstract][Full Text] [Related]
5. Lung Adenocarcinoma Harboring
Li J; Yan J; Cao R; Du G; Zhao G
Front Oncol; 2020; 10():575739. PubMed ID: 33392076
[TBL] [Abstract][Full Text] [Related]
6. Role of the EGFR-KDD mutation as a possible mechanism of acquired resistance of non-small cell lung cancer to EGFR tyrosine kinase inhibitors: A case report.
He C; Wang Y
Mol Clin Oncol; 2022 Feb; 16(2):30. PubMed ID: 34987800
[TBL] [Abstract][Full Text] [Related]
7. A Lung Adenocarcinoma Patient With a Rare
Wei Y; Cui Y; Guo Y; Li L; Zeng L
Front Oncol; 2021; 11():700345. PubMed ID: 34178699
[TBL] [Abstract][Full Text] [Related]
8. Molecular diagnosis and clinical outcome of a lung cancer patient with
Yang D; Han X; Li D; Cui S; Liu S; Wu X; Dai Z
Am J Transl Res; 2020; 12(10):6689-6693. PubMed ID: 33194065
[TBL] [Abstract][Full Text] [Related]
9. Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report.
Wu L; Fang C; Zhao W; Li D; Tang S; Li X; Ji M
Ann Transl Med; 2022 Jan; 10(2):116. PubMed ID: 35282062
[TBL] [Abstract][Full Text] [Related]
10. Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report.
Zhang Y; Shen JQ; Shao L; Chen Y; Lei L; Wang JL
World J Clin Cases; 2021 Sep; 9(27):8220-8225. PubMed ID: 34621884
[TBL] [Abstract][Full Text] [Related]
11. Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors.
Kondo T; Kikuchi O; Yamamoto Y; Sunami T; Wang Y; Fukuyama K; Saito T; Nakahara H; Minamiguchi S; Kanai M; Sueyoshi A; Muto M
Oncologist; 2024 May; ():. PubMed ID: 38821532
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
13. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
Tanizaki J; Banno E; Togashi Y; Hayashi H; Sakai K; Takeda M; Kaneda H; Nishio K; Nakagawa K
Lung Cancer; 2016 Nov; 101():11-15. PubMed ID: 27794398
[TBL] [Abstract][Full Text] [Related]
14. Response to Afatinib in a Patient with NSCLC Harboring Novel
Lin L; Wu X; Yan S; Zhu Y; Yan Z; Lv D; Ge H
Onco Targets Ther; 2020; 13():9753-9757. PubMed ID: 33061454
[TBL] [Abstract][Full Text] [Related]
15. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
[TBL] [Abstract][Full Text] [Related]
16. Afatinib for the treatment of metastatic non-small cell lung cancer.
Joshi M; Rizvi SM; Belani CP
Cancer Manag Res; 2015; 7():75-82. PubMed ID: 25733926
[TBL] [Abstract][Full Text] [Related]
17. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
18. Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report.
An N; Wang H; Zhu H; Yan W; Jing W; Kong L; Zhang Y; Yu J
Onco Targets Ther; 2019; 12():7399-7404. PubMed ID: 31686847
[TBL] [Abstract][Full Text] [Related]
19. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
20. Complete Response to Afatinib of an EGFR Exon 18 delE709_T710insD-Mutated Stage IV Lung Adenocarcinoma.
Jelli B; Taton O; D'Haene N; Remmelink M; Mekinda Z
Eur J Case Rep Intern Med; 2021; 8(8):002749. PubMed ID: 34527619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
